Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Improved survival for adolescents and young adults with Hodgkin lymphoma and continued high survival for children in the Netherlands: a population-based study during 1990-2015.

Reedijk AMJ, Zijtregtop EAM, Coebergh JWW, Meyer-Wentrup FAG, Hebeda KM, Zwaan CM, Janssens GOR, Pieters R, Plattel WJ, Dinmohamed AG, Zijlstra JM, Kremer LCM, Lugtenburg PJ, Beishuizen A, Karim-Kos HE.

Br J Haematol. 2020 Feb 6. doi: 10.1111/bjh.16491. [Epub ahead of print]

PMID:
32030738
2.

Diagnostic Accuracy of Stool Tests for Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors.

Ykema B, Rigter L, Spaander M, Moons L, Bisseling T, Aleman B, de Boer JP, Lugtenburg P, Janus C, Petersen E, Roesink J, Raemaekers J, van der Maazen R, Lansdorp-Vogelaar I, Gini A, Verbeek W, Lemmens M, Meijer G, van Leeuwen F, Snaebjornsson P, Carvalho B, van Leerdam M.

J Clin Med. 2020 Jan 10;9(1). pii: E190. doi: 10.3390/jcm9010190.

3.

Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.

Chamuleau MED, Burggraaff CN, Nijland M, Bakunina K, Mous R, Lugtenburg PJ, Dierickx D, van Imhoff GW, Vermaat JSP, Marijt EAF, Visser O, Mandigers C, Bilgin YM, Beeker A, Durian MF, van Rees B, Bohmer LH, Tick LW, Boersma RS, Snijders TJF, Schouten HC, Koene HR, de Jongh E, Hijmering N, Diepstra A, van den Berg A, Arens AIJ, Huijbregts J, Hoekstra O, Zijlstra JM, de Jong D, Kersten MJ.

Haematologica. 2019 Dec 19. pii: haematol.2019.238162. doi: 10.3324/haematol.2019.238162. [Epub ahead of print]

4.

Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: a population-based analysis in the Netherlands, 1993-2016.

Posthuma HLA, Zijlstra JM, Visser O, Lugtenburg PJ, Kersten MJ, Dinmohamed AG.

Br J Haematol. 2019 Nov 4. doi: 10.1111/bjh.16290. [Epub ahead of print]

PMID:
31682006
5.

Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study.

Maggen C, Dierickx D, Lugtenburg P, Laenen A, Cardonick E, Smakov R, Bellido M, Cabrera-Garcia A, Gziri MM, Halaska MJ, Ottevanger PB, Van Calsteren K, O'Laughlin A, Polushkina E, Van Dam L, Avivi I, Vandenberghe P, Woei-A-Jin FJSH, Amant F; International Network on Cancer, Infertility and Pregnancy.

Lancet Haematol. 2019 Nov;6(11):e551-e561. doi: 10.1016/S2352-3026(19)30195-4. Epub 2019 Sep 26.

PMID:
31564649
6.

Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.

Lugtenburg PJ, Zijlstra JM, Doorduijn JK, Böhmer LH, Hoogendoorn M, Berenschot HW, Beeker A, van der Burg-de Graauw NC, Schouten HC, Bilgin YM, Kersten MJ, Koene HR, Herbers AHE, de Jong D, Hijmering N, Lam KH, Chiţu D, Brouwer RE, van Imhoff GW; Dutch HOVON group.

Br J Haematol. 2019 Nov;187(3):347-355. doi: 10.1111/bjh.16087. Epub 2019 Jul 10.

PMID:
31290569
7.

Patients' decision-making, experiences and preferences regarding pixantrone treatment in relapsed or refractory diffuse large B-cell lymphoma: study protocol for a longitudinal mixed methods study.

van Hoogdalem LE, Siemes C, Lugtenburg PJ, Busschbach JJV, Ismail SY.

BMJ Open. 2019 May 22;9(5):e026505. doi: 10.1136/bmjopen-2018-026505.

8.

Treatment and Survival of Patients With Primary Effusion Lymphoma in the Netherlands: A Population-based Analysis, 2002-2015.

Dinmohamed AG, Visser O, Doorduijn JK, Lugtenburg PJ.

Hemasphere. 2018 Oct;2(5):e143. doi: 10.1097/HS9.0000000000000143. Epub 2018 Oct 2.

9.

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.

Zelenetz AD, Salles G, Mason KD, Casulo C, Le Gouill S, Sehn LH, Tilly H, Cartron G, Chamuleau MED, Goy A, Tam CS, Lugtenburg PJ, Petrich AM, Sinha A, Samineni D, Herter S, Ingalla E, Szafer-Glusman E, Klein C, Sampath D, Kornacker M, Mobasher M, Morschhauser F.

Blood. 2019 May 2;133(18):1964-1976. doi: 10.1182/blood-2018-11-880526. Epub 2019 Mar 8.

10.

Treatment of aggressive non-Hodgkin's lymphoma in frail patients: cardiac comorbidities and advanced age.

Lugtenburg PJ, Lyon AR, Marks R, Luminari S.

Future Oncol. 2019 Apr;15(11):1197-1205. doi: 10.2217/fon-2019-0019. Epub 2019 Feb 7.

11.

[Incidental detection of maternal malignancy in non-invasive prenatal test].

Saes L, Govaerts LCP, Knapen MFCM, Lugtenburg PJ, Boere IA, Galjaard RH.

Ned Tijdschr Geneeskd. 2019 Jan 24;163. pii: D2779. Dutch.

PMID:
30698367
12.

Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer.

Rigter LS, Schaapveld M, Janus CPM, Krol ADG, van der Maazen RWM, Roesink J, Zijlstra JM, van Imhoff GW, Poortmans PMP, Beijert M, Lugtenburg PJ, Visser O, Snaebjornsson P, van Eggermond AM, Aleman BMP, van Leeuwen FE, van Leerdam ME.

Cancer Med. 2019 Jan;8(1):190-199. doi: 10.1002/cam4.1922. Epub 2018 Dec 27.

13.

High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors.

Rigter LS, Spaander MCW, Aleman BMP, Bisseling TM, Moons LM, Cats A, Lugtenburg PJ, Janus CPM, Petersen EJ, Roesink JM, van der Maazen RWM, Snaebjornsson P, Kuipers EJ, Bruno MJ, Dekker E, Meijer GA, de Boer JP, van Leeuwen FE, van Leerdam ME.

Cancer. 2019 Mar 15;125(6):990-999. doi: 10.1002/cncr.31903. Epub 2018 Dec 18.

14.

Comparing causes of death of Hodgkin lymphoma and breast cancer patients between medical records and cause-of-death statistics.

de Vries S, Schaapveld M, Kardaun JW, de Bruin KH, Krol AD, Lugtenburg PJ, Jacobse JN, Aleman BM, van Leeuwen FE.

Clin Epidemiol. 2018 Oct 16;10:1523-1531. doi: 10.2147/CLEP.S161359. eCollection 2018.

15.

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.

Hagenbeek A, Mooij H, Zijlstra J, Lugtenburg P, van Imhoff G, Nijland M, Tonino S, Hutchings M, Spiering M, Liu R, van Tinteren H, Kersten MJ.

Haematologica. 2019 Apr;104(4):e151-e153. doi: 10.3324/haematol.2018.196899. Epub 2018 Oct 31. No abstract available.

16.

A longitudinal and cross-sectional study ofEpstein-Barr virus DNA load: a possible predictor of AIDS-related lymphoma in HIV-infected patients.

Hijlkema SH, van Kampen JJA, Voermans JJC, den Oudsten MYE, Doorduijn J, van Lugtenburg PJ, van de Vijver DAMC, van der Ende ME.

Infect Dis (Lond). 2018 Nov - Dec;50(11-12):847-852. doi: 10.1080/23744235.2018.1508884. Epub 2018 Oct 14.

PMID:
30317893
17.

Swelling of the breast after cosmetic augmentation.

van 't Hart W, Jansen AJG, Lam KH, Lugtenburg PJ, Vasilic D.

Neth J Med. 2018 Sep;76(7):345. No abstract available.

18.

Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.

Franken MG, Kanters TA, Coenen JL, de Jong P, Koene HR, Lugtenburg PJ, Jager A, Uyl-de Groot CA.

Anticancer Drugs. 2018 Sep;29(8):791-801. doi: 10.1097/CAD.0000000000000648.

PMID:
29846248
19.

Interobserver Agreement of Interim and End-of-Treatment 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials.

Burggraaff CN, Cornelisse AC, Hoekstra OS, Lugtenburg PJ, De Keizer B, Arens AIJ, Celik F, Huijbregts JE, De Vet HCW, Zijlstra JM; HOVON Imaging Working Group.

J Nucl Med. 2018 Dec;59(12):1831-1836. doi: 10.2967/jnumed.118.210807. Epub 2018 May 4.

20.

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.

Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH.

J Clin Oncol. 2018 Aug 1;36(22):2259-2266. doi: 10.1200/JCO.2017.76.3656. Epub 2018 Mar 27.

PMID:
29584548
21.

Overrepresentation of patients from HTLV-1 endemic countries among T cell Non-Hodgkin lymphomas in the Netherlands: an indication of under-diagnosis of Adult T cell leukaemia/lymphoma.

van Tienen C, Visser O, Lugtenburg P, Taylor G, Cook L.

Br J Haematol. 2019 Feb;184(4):688-689. doi: 10.1111/bjh.15160. Epub 2018 Mar 12. No abstract available.

22.

High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors.

de Vries S, Schaapveld M, van Nimwegen FA, Jóźwiak K, Lugtenburg PJ, Daniëls LA, Roesink JM, van der Maazen RWM, Kok WEM, Aleman BMP, van Leeuwen FE.

Br J Cancer. 2018 Mar 20;118(6):887-895. doi: 10.1038/bjc.2017.476. Epub 2018 Jan 30.

23.

Treatment and relative survival in very elderly patients with DLBCL in The Netherlands: a population-based study, 1989 to 2015.

Dinmohamed AG, Issa DE, van der Poel MWM, Schouten HC, Lugtenburg PJ, Chamuleau MED, Zweegman S, Visser O.

Blood Adv. 2017 Sep 22;1(21):1839-1841. doi: 10.1182/bloodadvances.2017011031. eCollection 2017 Sep 26. No abstract available.

24.

Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial.

Thomas J, Fermé C, Noordijk EM, Morschhauser F, Girinsky T, Gaillard I, Lugtenburg PJ, André M, Lybeert MLM, Stamatoullas A, Beijert M, Hélias P, Eghbali H, Gabarre J, van der Maazen RWM, Jaubert J, Bouabdallah K, Boulat O, Roesink JM, Christian B, Ong F, Bordessoule D, Tertian G, Gonzalez H, Vranovsky A, Quittet P, Tirelli U, de Jong D, Audouin J, Aleman BMP, Henry-Amar M.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1133-1145. doi: 10.1016/j.ijrobp.2017.10.015. Epub 2017 Oct 27.

PMID:
29229324
25.

Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.

Davies A, Berge C, Boehnke A, Dadabhoy A, Lugtenburg P, Rule S, Rummel M, McIntyre C, Smith R, Badoux X.

Adv Ther. 2017 Oct;34(10):2210-2231. doi: 10.1007/s12325-017-0610-z. Epub 2017 Oct 5. Review.

26.

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.

Lugtenburg P, Avivi I, Berenschot H, Ilhan O, Marolleau JP, Nagler A, Rueda A, Tani M, Turgut M, Osborne S, Smith R, Pfreundschuh M.

Haematologica. 2017 Nov;102(11):1913-1922. doi: 10.3324/haematol.2017.173583. Epub 2017 Sep 21.

27.

Randomized controlled trial on the effects of a supervised high intensity exercise program in patients with a hematologic malignancy treated with autologous stem cell transplantation: Results from the EXIST study.

Persoon S, ChinAPaw MJM, Buffart LM, Liu RDK, Wijermans P, Koene HR, Minnema MC, Lugtenburg PJ, Marijt EWA, Brug J, Nollet F, Kersten MJ.

PLoS One. 2017 Jul 20;12(7):e0181313. doi: 10.1371/journal.pone.0181313. eCollection 2017.

28.

ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial.

Fermé C, Thomas J, Brice P, Casasnovas O, Vranovsky A, Bologna S, Lugtenburg PJ, Bouabdallah R, Carde P, Sebban C, Eghbali H, Salles G, van Imhoff GW, Thyss A, Noordijk EM, Reman O, Lybeert MLM, Janvier M, Spina M, Audhuy B, Raemaekers JMM, Delarue R, Anglaret B, de Weerdt O, Marjanovic Z, Tersteeg RJHA, de Jong D, Brière J, Henry-Amar M; European Organisation for Research and Treatment of Cancer Lymphoma Group, and; Groupe d'Étude des Lymphomes de l'Adulte.

Eur J Cancer. 2017 Aug;81:45-55. doi: 10.1016/j.ejca.2017.05.005. Epub 2017 Jun 8.

PMID:
28601705
29.

Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design.

Rigter LS, Spaander MC, Moons LM, Bisseling TM, Aleman BM, de Boer JP, Lugtenburg PJ, Janus CP, Petersen EJ, Roesink JM, Raemaekers JM, van der Maazen RW, Cats A, Bleiker EM, Snaebjornsson P, Carvalho B, Lansdorp-Vogelaar I, Jóźwiak K, Te Riele H, Meijer GA, van Leeuwen FE, van Leerdam ME.

BMC Cancer. 2017 Feb 7;17(1):112. doi: 10.1186/s12885-017-3089-8.

30.

Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines.

van Nimwegen FA, Ntentas G, Darby SC, Schaapveld M, Hauptmann M, Lugtenburg PJ, Janus CPM, Daniels L, van Leeuwen FE, Cutter DJ, Aleman BMP.

Blood. 2017 Apr 20;129(16):2257-2265. doi: 10.1182/blood-2016-09-740332. Epub 2017 Jan 31.

31.

Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.

Cheson BD, Trask PC, Gribben JG, Dimier N, Kimby E, Lugtenburg PJ, Thieblemont C, Wassner-Fritsch E, Launonen A, Sehn LH.

Ann Hematol. 2017 Feb;96(2):253-259. doi: 10.1007/s00277-016-2878-5. Epub 2016 Nov 30.

32.

Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up.

Liu L, Giusti F, Schaapveld M, Aleman B, Lugtenburg P, Meijnders P, Hutchings M, Lemmens V, Bogaerts J, Visser O.

Br J Haematol. 2017 Jan;176(1):65-75. doi: 10.1111/bjh.14379. Epub 2016 Oct 21.

PMID:
27766636
33.

Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.

Doorduijn JK, van Imhoff GW, van der Holt B, Schouten HC, Schaafsma MR, MacKenzie MA, Baars JW, Kersten MJ, Lugtenburg PJ, van den Bent MJ, Enting RH, Spoelstra FM, Poortmans P, Bromberg JEC.

Hematol Oncol. 2017 Dec;35(4):497-503. doi: 10.1002/hon.2342. Epub 2016 Aug 17.

PMID:
27530779
34.

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.

Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD.

Lancet Oncol. 2016 Aug;17(8):1081-1093. doi: 10.1016/S1470-2045(16)30097-3. Epub 2016 Jun 23.

PMID:
27345636
35.

Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.

Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N.

J Clin Oncol. 2016 Jun 10;34(17):2028-36. doi: 10.1200/JCO.2015.64.5648. Epub 2016 Apr 25.

PMID:
27114593
36.

Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.

Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE.

N Engl J Med. 2015 Dec 24;373(26):2499-511. doi: 10.1056/NEJMoa1505949.

37.

Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life.

Chong GL, Broekman F, Polinder S, Doorduijn JK, Lugtenburg PJ, Verbon A, Cornelissen JJ, Rijnders BJ.

Int J Antimicrob Agents. 2015 Jul;46(1):82-7. doi: 10.1016/j.ijantimicag.2015.02.023. Epub 2015 Apr 15.

PMID:
25956843
38.

Multiple venous aneurysms in a patient with hypereosinophilic syndrome.

Malskat WS, Racz E, ten Raa S, Lugtenburg PJ, Hegt VN, de Maeseneer MG.

Phlebology. 2016 Feb;31(1):66-8. doi: 10.1177/0268355514564176. Epub 2014 Dec 9.

PMID:
25505272
39.

B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma.

van der Velden VH, Hoogeveen PG, de Ridder D, Schindler-van der Struijk M, van Zelm MC, Sanders M, Karsch D, Beverloo HB, Lam K, Orfao A, Lugtenburg PJ, Böttcher S, van Dongen JJ, Langerak AW, Kappers-Klunne M, van Lom K.

Blood. 2014 Jul 17;124(3):412-9. doi: 10.1182/blood-2013-10-533869. Epub 2014 Jun 2.

PMID:
24891323
40.

Risk of multiple primary malignancies following treatment of Hodgkin lymphoma.

van Eggermond AM, Schaapveld M, Lugtenburg PJ, Krol AD, de Boer JP, Zijlstra JM, Raemaekers JM, Kremer LC, Roesink JM, Louwman MW, Aleman BM, van Leeuwen FE.

Blood. 2014 Jul 17;124(3):319-27; quiz 466. doi: 10.1182/blood-2013-10-532184. Epub 2014 Apr 16.

PMID:
24740811
41.

Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C.

J Clin Oncol. 2014 Apr 20;32(12):1188-94. doi: 10.1200/JCO.2013.51.9298. Epub 2014 Mar 17.

PMID:
24637998
42.

Healthcare utilisation in patients with breast cancer or non-Hodgkin lymphoma who experienced febrile neutropenia in the Netherlands: a retrospective matched control study using the PHARMO database.

Issa DE, Gelderblom H, Lugtenburg PJ, van Herk-Sukel MP, Houweling LM, De La Orden M, van der Werf-Langenberg ME, Nortier JW, de Jong FA.

Eur J Cancer Care (Engl). 2015 Mar;24(2):232-41. doi: 10.1111/ecc.12189. Epub 2014 Feb 14.

PMID:
24528512
43.

Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study.

van der Kaaij MA, van Echten-Arends J, Heutte N, Meijnders P, Abeilard-Lemoisson E, Spina M, Moser EC, Allgeier A, Meulemans B, Lugtenburg PJ, Aleman BM, Noordijk EM, Fermé C, Thomas J, Stamatoullas A, Fruchart C, Eghbali H, Brice P, Smit WG, Sebban C, Doorduijn JK, Roesink JM, Gaillard I, Coiffier B, Lybeert ML, Casasnovas O, André M, Raemaekers JM, Henry-Amar M, Kluin-Nelemans JC; European Organisation for Research and Treatment of Cancer Lymphoma Group and the Groupe d’Étude des Lymphomes de l'Adulte.

Hum Reprod. 2014 Mar;29(3):525-33. doi: 10.1093/humrep/det430. Epub 2013 Dec 17.

PMID:
24345581
44.

Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.

Lugtenburg P, Silvestre AS, Rossi FG, Noens L, Krall W, Bendall K, Szabo Z, Jaeger U.

Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):297-305. doi: 10.1016/j.clml.2012.06.004.

PMID:
23040435
45.

Parenthood in survivors of Hodgkin lymphoma: an EORTC-GELA general population case-control study.

van der Kaaij MA, Heutte N, Meijnders P, Abeilard-Lemoisson E, Spina M, Moser LC, Allgeier A, Meulemans B, Dubois B, Simons AH, Lugtenburg PJ, Aleman BM, Noordijk EM, Fermé C, Thomas J, Stamatoullas A, Fruchart C, Brice P, Gaillard I, Doorduijn JK, Sebban C, Smit WG, Bologna S, Roesink JM, Ong F, André MP, Raemaekers JM, Henry-Amar M, Kluin-Nelemans HC.

J Clin Oncol. 2012 Nov 1;30(31):3854-63. doi: 10.1200/JCO.2011.40.8906. Epub 2012 Sep 24.

PMID:
23008303
46.

Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (±R) CHOP.

Pettengell R, Silvestre AS, Schwenkglenks M, Rossi FG, Duehrsen U, Verhoef G, Lugtenburg PJ, Wheeler T, Pujol B, Haioun C.

Hematology. 2013 Jan;18(1):26-9. doi: 10.1179/1607845412Y.0000000033. Epub 2012 Sep 12.

47.

Treatment of older patients with mantle-cell lymphoma.

Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH.

N Engl J Med. 2012 Aug 9;367(6):520-31. doi: 10.1056/NEJMoa1200920.

48.

Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration.

de Graaff E, Maat P, Hulsenboom E, van den Berg R, van den Bent M, Demmers J, Lugtenburg PJ, Hoogenraad CC, Sillevis Smitt P.

Ann Neurol. 2012 Jun;71(6):815-24. doi: 10.1002/ana.23550. Epub 2012 Mar 23.

PMID:
22447725
49.

The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.

Salar A, Haioun C, Rossi FG, Duehrsen U, Pettengell R, Johnsen HE, Jaeger U, Verhoef G, Schwenkglenks M, Bacon P, Bendall K, Lugtenburg PJ.

Leuk Res. 2012 May;36(5):548-53. doi: 10.1016/j.leukres.2012.02.002. Epub 2012 Mar 3.

PMID:
22385870
50.

Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study.

van der Kaaij MA, Heutte N, Meijnders P, Abeilard-Lemoisson E, Spina M, Moser EC, Allgeier A, Meulemans B, Simons AH, Lugtenburg PJ, Aleman BM, Noordijk EM, Fermé C, Thomas J, Stamatoullas A, Fruchart C, Brice P, Gaillard I, Bologna S, Ong F, Eghbali H, Doorduijn JK, Morschhauser F, Sebban C, Roesink JM, Bouteloup M, Van Hoof A, Raemaekers JM, Henry-Amar M, Kluin-Nelemans HC.

J Clin Oncol. 2012 Jan 20;30(3):291-9. doi: 10.1200/JCO.2011.37.1989. Epub 2011 Dec 19.

PMID:
22184372

Supplemental Content

Loading ...
Support Center